Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) announced that it has received Breakthrough Therapy Designation (BTD) from the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) for its novel small-molecule FGFR4 inhibitor irpagratinib. The designation underscores the drug’s potential in treating hepatocellular carcinoma (HCC).
Irpagratinib’s Innovative Profile
Irpagratinib, discovered and developed by Abbisko, targets FGFR4 to treat HCC with FGF19 overexpression. Currently, no similar drug has been approved globally, positioning irpagratinib as a potential first-in-class therapy for this indication.-Fineline Info & Tech
